Puma Biotechnology Inc (PBYI)

Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that the U.

Cramer says he's still a believer in Salesforce and its CEO, Marc Benioff, despite the last quarter's results.

Cramer said the market is a ball of confusion and he doesn't blame any investor for sitting on the sidelines a while.

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Puma Biotechnology, Inc. , where a total volume of 3,028 contracts has been traded thus far today, a contract volume which is representative of approximately 302,800 underlying shares (given that every 1 contract represents 100 underlying shares).

Biotech stocks dominate our list of top charts today. Here are four to watch.

Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that the Marketing Authorization Application (MAA) for neratinib has been validated by the European Medicines Agency (EMA).

Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, today announced financial results for the second quarter ended June 30, 2016.

TheStreet's Adam Feuerstein answers reader questions about biotech stocks.

General Electic shares dipped as industrial orders waned in the second quarter.

Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced updated results from the Phase III clinical trial of Puma's investigational drug PB272 (neratinib) for the extended adjuvant treatment of...

Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, has submitted a New Drug Application (NDA) to the U.

Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that the positive results from the I-SPY 2 Phase II clinical trial of neratinib for the neoadjuvant treatment of breast cancer were published in...

Besides Sanofi, Biogen is the next most likely to complete a sizable transaction in the next 12 months, according to Credit Suisse analysts.

Cramer is taking Southwest Airlines over United Continental while Palo Alto Networks is good value but not great.

Three of Cramer's four FANG stocks still perform but the fourth can easily be replaced by these two companies.

Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that it has submitted its Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for neratinib.

Investors in Puma Biotechnology, Inc. saw new options begin trading today, for the August 19th expiration.

The most recent short interest data has been released for the 05/31/2016 settlement date, which shows a 530,564 share increase in total short interest for Puma Biotechnology, Inc. , to 5,028,719, an increase of 11.80% since 05/13/2016.

Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, presented positive results from an investigator-sponsored Phase II trial of neratinib with HER2-mutated, non-amplified breast cancer.

Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced the release of an abstract on its drug candidate PB272 (neratinib) that will be presented at the American Society of Clinical Oncology (ASCO)...

Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that Alan H.

Investors in Puma Biotechnology, Inc. saw new options begin trading today, for the July 1st expiration.

Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2016.

Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that Alan H.

Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that its drug candidate neratinib was highlighted in three poster presentations at the American Association for Cancer Research (AACR) Annual...

Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that results from the NEfERT-T Phase II clinical trial of neratinib in ERBB2-positive metastatic breast cancer patients were published online in...

Puma Biotechnology (PBYI) stock is lower in early-morning trading on Tuesday after the company announced that it will delay filing its New Drug Application (NDA) for a breast cancer drug.

Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that based on its recent meetings with the U.